5 November 2021 in Epidemiology and Vaccinal Prevention
Relevance. Currently, the national calendar of preventive vaccinations does not provide for revaccination against whooping cough in children over the age of 18 months. At the same time, the epidemiological and economic feasibility of revaccination against whooping cough in children aged 6–7 years, as well as adolescents, has been demonstrated in world practice. Aim. Based on a mathematical model, develop a forecast of pertussis morbidity dynamics and assess the potential socio-economic damage under the current and expanded vaccine prophylaxis algorithms.Methods. Mathematical modeling of the potential effect of revaccination against whooping cough in children aged 6–7 years (scenario 1) and at 6–7 years and 14 years (scenario 2) was carried out within the framework of the national calendar of preventive vaccinations. A simulation dynamic mathematical model is constructed that allows predicting the development of the epidemiological process of whooping cough on the basis of the dynamics of the main indicators of its prevalence in the population that developed in previous years. The model took into account dynamic changes in the preventive effectiveness of vaccinations and the potential level of underestimation of morbidity. The obtained arrays of indicators served as the basis for extrapolating trends in morbidity and mortality until 2034.The calculation of epidemiological benefits was carried out in the metrics of prevented loss of years of life under the two scenarios under consideration in comparison with the current vaccination algorithm. The calculation of the economic effect was carried out on the basis of the obtained indicators of epidemiological benefits in the metrics of the monetary equivalent of the average cost of a year of life, taking into account the projected inflation coefficients until 2034.Results. The projected decrease in the number of years of life lived in a state of illness, in comparison with the current situation, will total 44.5 thousand years for the period 2019–2034 under scenario 1 and 66.7 thousand years under scenario 2. The socio-economic damage from prevented cases of the disease, expressed in the monetary equivalent of the average cost of living, will decrease by 28.6% (scenario 1) or 42.0% (scenario 2).Conclusions. A comparison of the received public benefits with the costs of vaccination shows that the expansion of the NCPP with additional revaccinations against whooping cough (at 6–7 years or at 6–7 and at 14 years) is advisable both in epidemiological and economic aspects.
14 March 2023 in Real-World Data & Evidence
Mass vaccination against pertussis in our country has decreased the frequency of this infection. The lack of the total vaccination in children in 80-90 yy XX c led to the growth of morbidity in the current moment. Return in active vaccination / revaccination of population against pertussis is a demand of the time. Economic aspects of this kind approach to the social health care are required for an evaluation based on RWD.Materials and methods: Calculation of the macroeconomic effects of vaccination against pertussis has been performed with Far East Federal Region (FEFR) example for buster in children 6-7 y. o. based on RWD and prognosis of morbidity annually. A unique model of the epidemiology of pertussis in FEFR has been created with RWD statistics and the Global burden of diseases project usage. The size of the virtual cohort of children 6-7 y. o. was established as 100 thousand. It has been assumed that 95 % from this cohort will receive buster of the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, combined, adsorbed (INN) with its efficacy and cost consideration. The monetary equivalent of the epidemiologic benefit due to disease prevention in the vaccinated children with regional GDP per capita has been calculated.Results: The total summarized benefit due to illness prevention after buster in children in FEFR could be as 21,15 mln RUR annually, and due to mortality reduction in the life years expectation horizon — of 50,45 mln RUR. The total economic profit of the buster revaccination against pertussis in children 6-7 y. o. with its influence on morbidity in children of younger age groups can lead to 198,69 bln RUR during the 7-year horizon of vaccine efficacy.Conclusion: RWD is a base for modeling and potential prognosis of epidemiological process and results of this job are proved the economic necessity for buster vaccination against pertussis in children 6-7 y. o. in the Russian Federation.
28 August 2023 in Real-World Data & Evidence
Meningococcal infection (MI) is one of the heaviest illnesses with specific clinical picture and outcomes. MI prophylaxis is also actual from a social-economic viewpoint. Analysis based on RWD is important and should include epidemiological, medical, regional economic parameters as well as demographic data.Aim: economic evaluation of the potential outcomes of vaccination against MI in Far East Federal District of Russia (FER) in frames of vaccination growth in children.Materials and methods: Modelling of epidemiological and economic outcomes of MI vaccination with MenACWY-D vaccine in 95% of 3-year-old children in FER. Economic model usage cost vaccination, its efficacy, morbidity after vaccine usage, and mortality with such kind of parameters comparison w/o vaccination. The economic gain of vaccination is calculated in terms of the prevented loss of life years and the monetary equivalent of the per capita domestic regional product.Results: Vaccination against MI in 100 thousand children aged 3 years will decrease morbidity by 64,5% and mortality by 75% during 8 years after vaccination. Social gain is 5,8 mln RUR due to morbidity decrease and 1,3 bln RUR due to saving lives.Conclusion: Vaccination has an economic advantage — benefit after 100 thousand children vaccination up to 4,3 times higher than cost of vaccination in FER.
2 August 2022 in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
Meningococcal infection (MI) is one of the severe illnesses by clinical manifestations and their consequences. Specific prophylaxis of severe MI forms is the most effective measure in the current conditions. It can lead to morbidity and disability reduction as well as and economic burden cut. Aim. Potential economic benefits of society finding in case of meningococcal polysaccharide conjugate vaccine to prevent MI caused by serogroups A, C, W, and Y into the National calendar of prophylactic vaccines (NCPV) for children 9- and 12-months age. Material and methods. The dynamic simulation mathematical model for epidemiological consequences of MI vaccines prophylaxis inclusion into NCPV was created. And economic calculations have been made based on this model also. Cost of vaccination based on prognosis of children amount in age before one year has been calculated, monetary equivalent of economic burden reduction in case of MI vaccines prophylaxis inclusion into NCPV was created. Results. Vaccination reduces mortality on 58–60 %, especially in children less than 5 years old. Correlation of the total epidemiological benefits expressed in years of prevented years of lost life with the projected cost of a statistical year of life gives the following results: starting from the 1st year of vaccination of children, society will receive almost 6.5 billion RUR monetary gain in metrics of life saved years. Monetary benefit on 10 years horizon could be as 70 billion RUR. Conclusion. Expenditures for meningococcal polysaccharide conjugate vaccine to prevent MI caused by serogroups A, C, W, and Y usage in case of inclusion into NCPV for children in 9- and 12-months (twice in the first year of life) are economic proved in frames of monetary equivalent of society gain in certain conditions.
1 January 2021 in Obstetrics and gynecology: News, Opinions, Training
Micronutrient provision of women in the Russian Federation: impact on the favorable course of pregnancy, perinatal outcomes and demographic indicators
14 October 2023 in Real-World Data & Evidence
Actuality. Previously, we calculated the economic consequences of the booster vaccination against pertussis infection (CI) with the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, combined, adsorbed (INN) in some regions of the Russian Federation, which showed that the public benefit within 7 years after immunization could potentially exceed the cost of vaccination 1.23 times. At the same time, it is important to provide an economic justification for vaccination for a megalopolis, such as Moscow, with an underestimation of the diagnosis of the disease in conditions of high population density, contributing to the spread of infection. Materials and methods. The assessment of the economic benefits of obtaining an epidemiological gain during revaccination was carried out within the framework of a market economy using an assessment of the cost of the disease. The calculations were based on data on the cost of CI treatment in Moscow, considering cases of complicated and mild course and on the basis of current tariffs of the OMI system. Modeling was performed based on morbidity rates, taking into account the underestimation of detectability in a cohort of 14-year-olds numbering 100 thousand people. Two scenarios were compared, providing for the preservation of the existing procedure of revaccination only at 6 years (95% coverage) and the scenario in which the second revaccination of all adolescents was carried out at 14 years. Using the model, epidemiological indicators of changes in the incidence of CI were determined, and direct and indirect costs were calculated on their basis. When testing the sensitivity of the model, other levels of vaccination of 14-year-old children were also used in the calculations. Results. Booster revaccination of a conditional cohort of 100,000 children aged 14 years with the mentioned vaccine will reduce the incidence of pertussis during the period of saving immune protection (7 years) by 53.7% (from 1702.5 to 788.4 cases per 100 thousand of the population of these ages). This epidemiological gain will be accompanied by an economic benefit calculated in the metric of the total cost of prevented cases of the disease, which will amount to 155.4 million rubles. For a cohort of 100 thousand revaccinated adolescents of 14 years. The economic benefits accompanying a potential reduction in the incidence of infants can range from 254.4 to 470.5 million rubles, depending on the nature and intensity of contacts between adolescents and younger children. Conclusion. With the given parameters of underestimating the diagnosis and cost of the vaccine in the population over 14 years of age in Moscow, revaccination of adolescents is an economically justified measure.